Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Regal Investment Advisors LLC

Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 88.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 27,204 shares of the company’s stock after acquiring an additional 12,745 shares during the period. Regal Investment Advisors LLC’s holdings in Werewolf Therapeutics were worth $40,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOWL. XTX Topco Ltd purchased a new stake in Werewolf Therapeutics during the 3rd quarter valued at about $45,000. Levin Capital Strategies L.P. acquired a new stake in shares of Werewolf Therapeutics during the fourth quarter worth about $74,000. Barclays PLC boosted its position in Werewolf Therapeutics by 130.1% in the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after buying an additional 30,990 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Werewolf Therapeutics by 372.4% in the 4th quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after buying an additional 49,608 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Werewolf Therapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 71,300 shares of the company’s stock worth $106,000 after buying an additional 13,372 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Up 8.4 %

HOWL stock opened at $0.92 on Friday. The firm’s fifty day moving average is $1.10 and its 200 day moving average is $1.58. The firm has a market cap of $41.20 million, a PE ratio of -0.60 and a beta of 0.48. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $6.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

HOWL has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th. Finally, JMP Securities lowered their target price on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.